Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229717 | 0.91 | USP30 (0.53) | GPR119USP30MEN1KMT2A | |
| SCHEMBL5888078 | 0.90 | SLC6A2 (0.52) | GPR119USP30MEN1KMT2ASTS | |
| SCHEMBL5224399 | 0.90 | USP30 (0.52) | GPR119USP30MEN1KMT2A | |
| SCHEMBL5887872 | 0.90 | SLC6A2 (0.51) | GPR119USP30MEN1KMT2ASTS | |
| SCHEMBL5200443 | 0.90 | USP30 (0.52) | GPR119USP30MEN1KMT2A | |
| SCHEMBL5264788 | 0.88 | GPR119 (0.48) | GPR119USP30MEN1KMT2A | |
| SCHEMBL5887887 | 0.87 | GPR119 (0.48) | GPR119USP30MEN1KMT2A | |
| SCHEMBL5887710 | 0.85 | GPR119 (0.48) | GPR119USP30MEN1KMT2A | |
| SCHEMBL5888144 | 0.85 | GPR119 (0.47) | GPR119USP30MEN1KMT2A | |
| SCHEMBL5887980 | 0.83 | GPR119 (0.51) | GPR119USP30MEN1KMT2ASTS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817281-A1 | N- [(3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS | Pfizer Limited (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-7122683-B2 | Amides useful as monoamine re-uptake inhibitors | PFIZER INC. (US) | 2006-10-17 | — | — | US | disclosed |
| WO-2006056884-A1 | N- [ (3S)- PYRROLIDIN-3-YL]- BENZAMIDE DERIVATIVES AS MONOAMINE RE-UPTAKE INHIBITORS | PFIZER LIMITED (GB) | 2006-06-01 | — | — | WO | disclosed |
| US-20060111429-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | PFIZER INC | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111429-A1 | Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting | ADRB3, AOC3, HRH4 | GPR119 1434/4885USP30 1902/4885LMNA 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.